First Trust Advisors LP acquired a new stake in Assembly Biosciences Inc (NASDAQ:ASMB) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 43,723 shares of the biopharmaceutical company’s stock, valued at approximately $1,624,000.

Several other institutional investors also recently bought and sold shares of ASMB. Bank of Montreal Can bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $145,000. MetLife Investment Advisors LLC bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $282,000. Quantitative Systematic Strategies LLC bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $348,000. TD Asset Management Inc. boosted its holdings in shares of Assembly Biosciences by 20.5% in the second quarter. TD Asset Management Inc. now owns 9,400 shares of the biopharmaceutical company’s stock valued at $369,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Assembly Biosciences by 14.9% in the second quarter. Commonwealth Equity Services LLC now owns 10,497 shares of the biopharmaceutical company’s stock valued at $412,000 after acquiring an additional 1,365 shares in the last quarter. Institutional investors and hedge funds own 84.94% of the company’s stock.

A number of brokerages recently weighed in on ASMB. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a report on Tuesday, November 13th. B. Riley upgraded shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a report on Monday, October 8th. ValuEngine cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. Chardan Capital restated a “neutral” rating on shares of Assembly Biosciences in a report on Sunday, October 28th. Finally, Robert W. Baird began coverage on shares of Assembly Biosciences in a report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Assembly Biosciences presently has an average rating of “Buy” and a consensus target price of $52.00.

Shares of NASDAQ:ASMB opened at $24.69 on Thursday. The company has a market cap of $656.44 million, a P/E ratio of -10.24 and a beta of 1.45. Assembly Biosciences Inc has a 1-year low of $20.61 and a 1-year high of $67.36.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.14. The firm had revenue of $4.29 million during the quarter, compared to analysts’ expectations of $3.21 million. Assembly Biosciences had a negative net margin of 469.91% and a negative return on equity of 50.63%. On average, equities research analysts predict that Assembly Biosciences Inc will post -4.02 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “First Trust Advisors LP Invests $1.62 Million in Assembly Biosciences Inc (ASMB)” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/first-trust-advisors-lp-invests-1-62-million-in-assembly-biosciences-inc-asmb/2663902.html.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Recommended Story: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.